WebSep 23, 2015 · Introduction. Current guidelines call for lifelong aspirin (acetylsalicylic acid; ASA) with consideration of up to 6 months of clopidogrel following transcatheter aortic valve replacement (TAVR) [].Recently, small studies have questioned the necessity of dual antiplatelet therapy (DAPT) following the procedure [].Furthermore, many patients … WebSep 1, 2024 · The antiplatelet medication of choice for patients undergoing transcatheter aortic valve replacement (TAVR) has been derived empirically. Periprocedural stroke and adverse cardiac events have been associated with worse outcomes at 30 days and 1 year after TAVR, with half of these events occurring after 24 hours.1–3 Dual antiplatelet …
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement
http://mdedge.ma1.medscape.com/cardiology/article/220158/interventional-cardiology-surgery/voyager-pad-clopidogrel-adds-no-benefit WebDec 23, 2024 · Dual antiplatelet therapy (DAPT) was the initial antithrombotic regimen of choice following transcatheter aortic valve replacement (TAVR). Subsequent … fnf bacman
An Update on Anti-thrombotic Therapy Following Transcatheter …
WebApr 10, 2024 · Transcatheter aortic valve implantation (TAVI) is a well-established treatment strategy for symptomatic and severe aortic stenosis, supported by multiple randomised controlled trials across the spectrum of surgical risk. 1,2 However, thromboembolic and bleeding complications remain a major concern following the procedure, exacerbated by … WebApr 13, 2024 · The multicentre ADAPT TAVR (Edoxaban vs. DAPT in reducing subclinical leaflet thrombosis and Cerebral Thromboembolism After TAVR) randomised 229 patients (mean age 80.1 years; 41.9% men) undergoing TAVR for symptomatic severe AS, and without other indication for OAC, to edoxaban 60 mg or 30 mg once daily versus DAPT … WebSep 15, 2024 · A successful TAVR is defined as device success according to the VARC-2 criteria: correct positioning of a single prosthetic heart valve into the proper anatomical location AND Intended performance of the prosthetic heart valve (no prosthesis- patient mismatch* and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s, no … fnf bacon midi